Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
15.62
+0.31 (2.02%)
At close: Dec 5, 2025, 4:00 PM EST
15.71
+0.09 (0.58%)
After-hours: Dec 5, 2025, 7:20 PM EST
Aurinia Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Aurinia Pharmaceuticals stock have an average target of 17.25, with a low estimate of 15 and a high estimate of 21. The average target predicts an increase of 10.44% from the current stock price of 15.62.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Aurinia Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 2 | 2 | 2 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $15 → $16 | Buy → Hold | Downgrades | $15 → $16 | +2.43% | Dec 3, 2025 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $10 → $21 | Hold → Strong Buy | Upgrades | $10 → $21 | +34.44% | Nov 7, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $9 → $15 | Buy → Hold | Downgrades | $9 → $15 | -3.97% | Nov 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $8 → $9 | Buy | Maintains | $8 → $9 | -42.38% | Aug 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +8.83% | Jul 30, 2025 |
Financial Forecast
Revenue This Year
285.02M
from 235.13M
Increased by 21.22%
Revenue Next Year
328.91M
from 285.02M
Increased by 15.40%
EPS This Year
0.76
from 0.04
Increased by 1,797.20%
EPS Next Year
0.91
from 0.76
Increased by 20.07%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 296.7M | 377.5M | ||||
| Avg | 285.0M | 328.9M | ||||
| Low | 267.7M | 292.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 26.2% | 32.4% | ||||
| Avg | 21.2% | 15.4% | ||||
| Low | 13.9% | 2.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.84 | 1.40 | ||||
| Avg | 0.76 | 0.91 | ||||
| Low | 0.67 | 0.63 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2,000.0% | 84.0% | ||||
| Avg | 1,797.2% | 20.1% | ||||
| Low | 1,566.0% | -17.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.